|

Pyrotinib Clinical Trials

23 actively recruiting trials

▲ +1 trial since August 2026

Also known as: Pyrotinib maleate, SHR1258

Pipeline

Phase 2: 12Phase 3: 4Phase 4: 2Phase 1/2: 2Phase 2/3: 1

Top Sponsors

  • The First Affiliated Hospital with Nanjing Medical University2
  • Sun Yat-sen University2
  • Shengjing Hospital2
  • Shanghai Jiao Tong University School of Medicine2
  • RenJi Hospital2

Indications

  • Cancer23
  • Breast Cancer21
  • HER2-positive Breast Cancer7
  • Advanced Breast Cancer3
  • HER2 + Breast Cancer2

Other23 trials

A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
N/A
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Phase 2
Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
Phase 3
Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer
Phase 3
Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
Phase 2
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
Phase 2
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Phase 3
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
Phase 1/2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC
Phase 3
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
Phase 2
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
Phase 2
Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
Phase 2
Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Phase 2
Pyrotinib in Women With High-risk in Early Stage Breast Cancer
Phase 2
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
Phase 2
Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer
Phase 4
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
Phase 1/2
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
Phase 2
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Phase 4
The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
Phase 2/3
ctDNA in HER2+ EBC Neoadjuvant Treatment
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.